Summary Plasminogen activator (PA) is a serine protease existing in two forms known as tissue-type (t-PA) and urokinase-type (u-PA). To examine whether PA is related to the postoperative clinical course of human breast cancer, total PA activity, t-PA activity, u-PA activity, and immunoreactive t-PA were determined in tissue extracts from 144 breast cancer specimens. The patients were initially divided into four groups according to the postoperative clinical course: Group I (83 patients who are disease-free), Group II (20 patients whose first metastases were found only in bone), Group III (19 patients whose first metastases were found in both bone and lung), and Group IV (22 patients whose first metastases were found only in lung). Total PA activity was significantly lower in Groups, II, III and IV than in Group I. Both t-PA activity and t-PA antigen levels were also significantly lower in Groups II, III and IV than in Group I, while no significant difference was found in u-PA activity among these groups, indicating that low activity of total PA in Groups II, III and IV was due to a decrease in t-PA but not in u-PA. In the multivariate analyses, t-PA activity was found to be an independent prognostic factor for relapse-free survival. When four groups of patients were further analysed in terms of nodal status, both t-PA activity and antigen levels were markedly decreased in the node-negative Group II compared with the node-negative Groups III and IV or with the node-positive Groups II, III and IV. Of additional interest, u-PA activity was significantly higher in node-positive patients than in nodenegative patients with any group. The clinico-pathologic analyses of the patients in this series showed that node involvement and lymphatic invasion were more frequently positive in Groups III and IV than in Groups I and II. When 144 breast cancers were categorised in terms of combinations of oestrogen receptor (ER) and progesterone receptor (PgR) status, breast cancers which were positive for both receptors were found to contain the highest t-PA activity and antigen. This study provides provocative evidence suggesting a possible differential significance of t-PA and u-PA expression in human breast cancer.
Many transformed or malignant tumour cells are known to produce plasminogen activator (PA), a serine-type protease converting plasminogen to plasmin (Unkeless et al., 1975; Howett et al., 1978; Orenstein et al., 1983) . It is widely accepted that PA is intimately involved in the metastatic spread of tumour cells (Dano et al., 1985; Colombi et al., 1986; Mignatti et al., 1986; Reich et al., 1988; Ossowski et al., 1988; Markus et al., 1988; Yu et al., 1990; Testa et al., 1990; Hollas et al., 1991) . There are two main forms of PA: urokinase type (u-PA) and tissue-type (t-PA). While both catalyse cleavage of the peptide bond between Arg-Val in plasminogen, thus converting the proenzyme to plasmin, they differ in many aspects such as their molecular weight, immunological reactivity and amino acid sequence (Ny et al., 1984; Riccio et al., 1985; Blasi et al., 1988) .
PA expressed in breast cancer tissue has attracted attention as (i) it is induced by oestrogen in breast cancer cells in culture (Butler et al., 1983; Ryan et al., 1984; Yamashita et al., 1984 Yamashita et al., , 1992a Inada et al., 1991 Inada et al., , 1992 Mira-y-Lopez et al., 1991) , (ii) it correlates with oestrogen receptor (ER) and/or progesterone receptor (PgR) content in human breast cancer (Sutherland, 1980; Thorsen, 1982; Yamashita et al., 1986; Pacheco et al., 1988) , and (iii) there are analogous effects of hormones, including oestrogen, on breast cancer growth and PA expression (Mak et al., 1976; Mira-y-Lopez et al., 1983 Butler et al., 1986) . In a multivariate analysis we recently showed a significant association between low levels of total PA activity and poor prognosis of breast cancer patients and suggested the value of total PA assays as a prognostic indicator for disease-free and overall survival (Yamashita et al., 1993) . This was unexpected in the light of previous publications that showed a poorer disease-free and overall survival for breast cancer patients whose tumours contain an elevated u-PA activity and/or antigen Janicke et al., 1990) . In this study, we therefore evaluated the t-PA and u-PA components of total activity, in the hope that this might resolve the apparent discrepancy between our report and those of others.
We have previously measured the concentration of t-PA in tissue extracts from 27 human breast cancers and presented preliminary evidence that patients with only-bone metastases had significantly less t-PA antigen level in their primary breast tumours than those with metastases to other organs (Yamashita et al., 1992b) . We have now extended this study and determined not only t-PA antigen level but also t-PA and u-PA activities in primary breast cancer tissues. These enzyme activities are compared with the postoperative clinical course of the patients. We report here that (i) a greater proportion of total PA activity is composed of t-PA in primary breast cancer tissues, and a decrease in t-PA, but not u-PA, is responsible for the low activity of total PA in patients with poor prognosis, (ii) t-PA activity and antigen levels are extremely low in patients with only-bone metastases from node-negative breast cancers, (iii) it is u-PA rather than t-PA that is involved in lymphatic dissemination which and lung simultaneously, or those whose first metastases were found in bone or lung and subsequently detected in the other site within 12 months), and Group IV (22 patients whose first metastases were found only in lung and remained confined in lung within 12 months. Group III included 3 patients who had also liver metastases. The median follow-up for patients in each group was: Group I, 9.1 years; Group II, 7.9 years; Group III, 7.2 years; and Group IV, 6.6 years.
The routine follow-up of these patients after surgery consisted of clinical evaluation every 3 months in the first year and every 6 months thereafter. Bloom and Richardson (1957) . ER and PgR were determined by the dextran-coated charcoal method as described previously (McGuire et al., 1977) . Tumour specimens were considered hormone receptorpositive if they contained at least 10 fmol specific binding sites mg-' protein.
Assay for PA The analyses in this study focused on whether or not the PA levels in the primary tumours differed among four groups. Samples for enzyme assay were prepared using 50 mM TrisHCl buffer (pH 7.4) containing 0.25% Triton X-100, as described previously (Yamashita et al., 1984) . Total PA activity was determined as described previously (Yamashita et al., 1984) in a coupled assay using S-2251 (H-D-Val-Leu-LyspNA, Kabi, Stockholm) as a substrate for plasmin. t-PA and u-PA activities were assayed according to the method of O'Grady et al. (1985) except that monoclonal antibodies to t-PA and u-PA (Cosmo Bio., Tokyo) were employed. Briefly, to measure the t-PA and u-PA activities, total PA activity was determined in the presence and absence of quenching antibodies against t-PA and u-PA. The activity in the presence of anti-t-PA antibody and anti-u-PA antibody was regarded as the u-PA and t-PA activity, respectively. In most cases, the proportion of activity quenched by anti-t-PA and anti-u-PA antibodies always added up to approximately 100%, indicating that t-PA and u-PA were the only forms of total PA present in the tissue extracts. The t-PA antigen level was determined with an enzyme-linked immunosorbent assay (ELISA) described by Bergsdorf et al. (1983 Cosmo Bio., Tokyo) was used as control. As sh6wn in Table  IV , t-PA activity/t-PA antigen (converted activity) ratio was significantly lower in patients with recurrence (Groups II, III and IV) than in recurrence-free patients (Group I) (P<0.001 both in node-negative groups and in node-positive groups).
Discussion
Previous studies have demonstrated a poorer disease-free and overall survival for breast cancer patients whose tumours contain an elevated u-PA activity and/or antigen Janicke et al., 1990) . However, in the retrospective study of early breast cancer patients, there was a statistically (42) 11 (55) 8 (42) 8 (36) 48(58) 9 (45) 11(58) 14 (64) 42 (51) 13 (65) 9 (47) 11 (50) 41(49) 7 (35) 10(53) 11 (50) 19 (23) 54 (65) 10 (12) 27 (33) 31 (37) 25 (30) 18 (22) 38 (46) 24 (29) 3 (4) 29 (35) 29 (35) 25 (30) 2 (10) 12 (60) 6 (30) 7 (35) (30) 2 (11) 13 (68) 4 (21) 2 (11) 8 (42) 9 (47) 1 (5) 10 (53) 8 (42) 0 (0) 4 (21) 7 (37) 8 (42) 4 (18) 14 (64) 4 (18) 2 (9) 6 (27) 14 (64) 2 (9) 1 (50) 9(41) 0 (0) 5 (23) 7 (32) 10 (45) 51 (61) 11 (55) 6 (32) 4 (18) 32(39) 9 (45) 13 (68) 18 (82) 46 (55) 7 (35) 9 (47) 12 (55) 37(45) 13 (65) 10 (53) 10 (45) 31 (37) 46 (55) 6 (7) 45 (54) 31 (37) 7 (8) 49 (59) 32 (39) 2 (2) 10 (12) 29 (35) 38 (46) 6 (7) 8 (40) 10 (50) 2 (10) 12 (60) 6 (30) 2 (10) 13 (65) 7 (35) 0 (0) 3 (15) 8 (40) 9 (45) 0 (0) 8 (42) 10 (53) 1 (5) 12 (63) 6 (32) 1 (5) 10 (53) 9 (47) 0 (0) 11 (50) 9 (41) 2 (9) 12 (55) 8 (36) 2 (9) 13 (59) 161 93 (converted activity) Activity/antigen ratio 0.55 ± 0.23a 0.17 ± 0.10 0.22 ± 0.12 0.16 ± 0.08 t-PA antigen levels were converted to activity by specific activity of t-PA (48.8 units ng -). All values represent the mean ± s.d.: t-PA activity and t-PA antigen (unit mg-' protein), activity/antigen ratio (%). Values in parentheses are the number of patients. aSignificant difference vs Groups II, III and IV; P<0.01. significant adverse association between low levels of total PA activity and patient survival (Yamashita et al., 1993) . The present study has resolved the discrepancy between these results. Our assay for total PA activity proved to be biased towards t-PA, that is, a greater proportion of total PA activity consisted of t-PA in breast cancer tissues, and therefore, a specific decrease in t-PA was responsible for the low activity of total PA seen in unfavourable groups of patients. Although the reason why a high t-PA activity in primary breast cancer tissues indicates a good prognosis remains unclear, this result is compatible with that reported by Duffy et al. (1988) . This may be related to the fact that t-PA is an oestrogen-inducible enzyme and thus reflects an intact ER system, since the presence of oestrogen dependency in breast cancer is generally thought to be associated with a good prognosis (Foekens et al., 1989) . Indeed, analyses of 144 patients in this series showed tumours which were positive for both ER and PgR contained significantly higher t-PA activity and antigen. In the multivariate analyses, t-PA activity was found to be a significant prognostic indicator. Patients with breast cancer containing high t-PA activity are considered to have a favourable prognosis, who might be candidates for being spared the necessity of adjuvant therapy.
Although bone metastases, without evidence of tumour deposits in other organs such as lung and liver, occur commonly in breast cancer, the mechanisms underlying the occurrence of these metastases are poorly understood. Metastases occur more commonly in the axial bones than in the appendicular bones, and often remain localised in the bone for a long time without any other evidence of metastases. One possible mechanism of this state of only-bone metastases is Batson's concept. Batson (1940) and Henriques et al. (1962) suggested that breast cancer may spread to the vertebral column and the axial bones through retrograde venous seeding without passing through the pulmonary circulation. Recently, Yamashita et al. (1991) also reported that patients who had bone metastases exclusively cranial to the lumbosacral junction had a significantly higher visceral metastases-free rate, and suggested an important role of vertebral venous plexus in only-bone metastases.
Tumour cell emboli were the most important event closely associated with the lodgement of the circulating tumour cells, and only tumour cell emboli with dense aggregation of platelets and formation of fibrin could develop into metastatic foci (Hilgard, 1973; Warren, 1973) . Furthermore, it has been stressed that the most important factors influencing the ability to form fibrin with clumping of tumour cells would be fibrinolytic activity of tumour cells themselves rather than that of blood itself (Warren, 1973; Kinjo, 1978) . While both t-PA and u-PA cleave the same single peptide bond in plasminogen to convert it into plasmin, t-PA is distinguished by its high affinity for fibrin. The binding of t-PA to fibrin causes a marked stimulation in its fibrinolytic activity (Holyaerts et al., 1982) . The present study demonstrated that t-PA activity and antigen levels in primary tumours are extremely low in patients with only-bone metastases from node-negative breast cancers, although the small numbers of patients in the various groups precluded a multivariate analysis. Thus, it is reasonable to expect that t-PA inhibits bone metastases formation by virtue of its fibrinolytic activity which may prevent the lodgement of cancer cells drifting in the vertebral venous plexus. Our interest in this hypothesis stems mainly from the possibility that t-PA may provide an effective strategy for prevention and treatment of bone metastases from human breast cancer. t-PA activity and antigen levels must be distinguished because of the inactivation of PA by PA inhibitors present in breast cancer tissues . There are at least two kinds of specific inhibitor which act on PA: type-I and type-2 PA inhibitors (PAI-I and PAI-2, respectively). PAI-i forms 1:1 complex with both u-PA and t-PA, and is thought to be a natural inhibitor of t-PA in plasma, although PAI-2 was shown to inhibit u-PA about ten times more strongly than t-PA (Astedt et al., 1987) . Although PA inhibitors in tissue extracts were not determined in this study, the t-PA activity/t-PA antigen ratio was significantly lower in patients with recurrence compared with recurrence-free patients, suggesting that PA inhibitors affected t-PA activity in tissue extracts to a greater extent in the former than in the latter. This relative increase in PA inhibition in unfavourable groups may be related to the fact that a significant positive correlation was found between PAI-I levels and the metastatic potential of breast cancer cells Sumiyoshi et al., 1991 Sumiyoshi et al., , 1992 . However, further studies are necessary in this respect.
With respect to u-PA, this enzyme is supposed to be a key enzyme in the breakdown of extracellular matrix proteins during tissue destruction in a variety of normal and pathological conditions, including the invasive growth and metastasis of cancer cells (Layer et al., 1987; Hearing et al., 1988; Yu et al., 1990; Ossowski et al., 1992) . The u-PAplasmin-collagenase activation cascade plays various important roles in facilitating cancer cell invasion (Paranjpe et al., 1980; Mignatti et al., 1986) . The present study also demonstrated that u-PA activity in the primary tumour was significantly higher in node-positive patients than in nodenegative patients. Furthermore, clinico-pathological analyses showed a preponderance of lymphatic extension in the group with lung-only or lung and bone metastases. These results suggested that u-PA is closely linked to lymphatic dissemination which subsequently developed into lung metastases.
In conclusion, this is the first report determining u-PA and t-PA levels in breast cancer tissues in terms of different patterns of metastatic spread. The results demonstrated here have provided provocative evidence suggesting a differential biological significance of t-PA and u-PA coexpressed in human breast cancer.
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